Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trialRobin Kate Kelley, Ming‐Huang Chen, Makoto Ueno et al.|The Lancet|2023Cited by 1k
Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 studyDo‐Youn Oh, Juan W. Valle, Jin Won Kim et al.|The Lancet. Gastroenterology & hepatology|2024Cited by 245
Identification of MALT1 as both a prognostic factor and a potential therapeutic target of regorafenib in cholangiocarcinoma patientsChun‐Nan Yeh, Ming‐Huang Chen|Oncotarget|2017Cited by 20
Immunoprofile of adenosquamous carcinoma in gastric cancerCheng-Han Wu, Ming‐Huang Chen|Journal of the Chinese Medical Association|2023Cited by 20